Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

QNCX Relative to the S&P 500

QNCX Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Quince Therapeutics, Inc. (NASD:QNCX) seasonal charts above shows that a Buy Date of December 11 and a Sell Date of March 22 has resulted in a geometric average return of 7.59% above the benchmark rate of the S&P 500 Total Return Index over the past 6 years. This seasonal timeframe has shown positive results compared to the benchmark in 4 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 6 years by an average of 51.88% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 6 years of data is available for shares of QNCX, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient s biology for the treatment of rare diseases. Its product includes EryDex, developed using their proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which is a novel device combination that uses an automated process designed to encapsulate a drug into the patient s own red blood cells. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.

To download QNCX seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: QNCX